The U.S. Justice Department properly sought dismissal of a whistleblower’s False Claims Act suit alleging a kickback scheme against drugmakers and pharmacy benefit managers including
A district court didn’t err in backing the DOJ’s determination that John R. Borzilleri’s suit accusing the companies of engaging in a fraudulent scheme to overcharge multiple sclerosis drugs under Medicare Part D would be too burdensome on government resources if allowed to continue, the U.S. Court of Appeals for the First Circuit ruled.
In ...